Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 110,331

Document Document Title
WO/2015/187905A1
The present invention relates to quinoline compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.  
WO/2015/187988A1
Current maintenance treatment for epilepsy (e.g., Dravet Syndrome and other intractable epilepsies) and/or epilepsy-related conditions remain under debate. Currently, the actions taken for epilepsy and/or epilepsy-related conditions invo...  
WO/2015/184542A1
The present application relates to novel compounds comprising a moiety that leads to the metabolic production of ketones bonded to a ketone- potentiated anti-epileptic drug, compositions comprising these compounds, and their use, for exa...  
WO/2015/187851A1
Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease o...  
WO/2015/185602A1
The invention discloses monocytes and/or a monocyte inducing agent and/or a monocyte activating agent and/or a monocyte recruiting agent for use in the treatment and prevention of PD.  
WO/2015/187289A1
This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.  
WO/2015/188142A1
Described herein are methods for diagnosing and monitoring traumatic brain injury by imaging a subject retinal to determine the presence and/or extent of deviations from a normal retina.  
WO/2015/184528A1
The present invention relates to botulinum toxins for use in the treatment of paratonia. In particular, the present invention relates to the treatment of paratonia by local administration of a botulinum toxin to a muscle of a patient.  
WO/2015/184509A1
H:\svm\Interwoven\NRPortbl\DCC\SVM\7886476_1.docx-5/06/2015 ABSTRACT The present invention relates generally to methods for the treatment and/or prophylaxis of neurological diseases and disorders involving administration of trans 10-HDA....  
WO/2015/184260A2  
WO/2015/180679A1
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I) : and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as def...  
WO/2015/183530A1
This invention provides a compound selected from the group consisting of L- nicotine(X1)(X2) and D-nicotine(X1)(X2), or a pharmaceutically acceptable salt thereof, wherein (i) each of Χ1 and X2 is independently a pharmaceutically accept...  
WO/2015/181449A1
The present invention relates to the field of medicine and in particular to Parkinson's disease (PD). Specifically the present invention relates to methods and means for early detection of PD. The invention relates also to methods and me...  
WO/2015/180060A1
Disclosed are a salt of diazacycloheptane compound and a crystal form and an amorphous substance thereof, which have improved features in the aspects of solubility, stability, dissolution of solid preparations and the like. Also disclose...  
WO/2015/182724A1
 Provided are compounds that are useful as prophylactic or therapeutic agents for various diseases involving T-type calcium channels, such as hypertension, arrhythmia, pain and cancer, said compounds having antagonistic activity agains...  
WO/2015/181640A1
A preparation comprising krill oil and phospholipids. Methods of treatment comprising administering the same.  
WO/2015/181094A1
The present invention relates to the therapeutic use of derivatives of 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid for improving the cognitive capacity of patients with intellectual disabilities, an IQ of less than 85, diagnose...  
WO/2015/184105A1
The present invention features methods for stimulating clearance of misfolded or aggregated proteins or peptides in microglia or neurons, and treating neurodegenerative diseases associated with such pathology in brain by selectively inhi...  
WO/2015/180342A1
The present invention provides a deuterium substituted 1-[2-(2,4-dimethyl-thiophenyl)-phenyl] piperazine compound with a structure represented by formula (I) or a derivative thereof, a pharmaceutical composition containing the compound o...  
WO/2015/184003A1
Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.  
WO/2015/180485A1
The present invention relates to an amantadine nitrate compound having a neuroprotective effect and a preparation and a medical use thereof. The compound has the structure of the general formula (I). The compound has multiple mechanisms ...  
WO/2015/184279A1
A method is provided for treating a Mendelian disorder of the epigenetic machinery (e.g., Kabuki syndrome) in a subject in need thereof. In particular, the method comprises administering to the subject a ketogenic composition in an amoun...  
WO/2015/183673A1
A TARP ϒ8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is; and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.  
WO/2015/181567A1
According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in the therapeutic treatment of a neurodegenerative disorder, such as Alzheimer's d...  
WO/2015/180582A1
Provided are a β crystalline form of aripiprazole hemiethanolate, a preparation method thereof and the use for preparing a I crystal form of aripiprazole with a low hygroscopicity. The preparation method for the β and I crystal forms o...  
WO/2015/182232A1
The purpose of the present invention is to provide a novel anti hallucination drug whereby hallucination symptoms can be suppressed, treated or prevented. The anti hallucination drug comprises a crude drug derived from a plant belonging ...  
WO/2015/181061A1
The invention relates to compounds of formula (I) wherein.....C.....is -CH2- or -CH2-CH2-; X is -NH-, -C(0)NH- or -NHC(0)NH-; Ar is phenyl or a 5 or 6-membered heteroaryl group containing one or two N atoms; R1 is halogen, lower alkyl, l...  
WO/2015/181336A1
The invention relates to a compound comprising the following general formula (1) for use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (1) wherein each of R1, R 2 and R 3 are...  
WO/2015/182723A1
 Provided are a novel pyrrolidine compound having melanocorin receptor agonist activity, a pharmacologically acceptable salt thereof, and pharmaceutical applications thereof. The present invention pertains to a pyrrolidine derivative r...  
WO/2015/181337A1
The invention relates to a compound comprising the following general formula (1) and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neur...  
WO/2015/179360A1
The present invention provides pharmaceutical compositions for treating neuromyelitis optica (NMO) comprising a therapeutically effective amount of loop C sequence-containing peptide of aquaporin-4 (AQP4) water channel, or a therapeutica...  
WO/2015/178020A1
The present invention relates to novel salts of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy }methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxyl ic acid. More particularly, the invention relates to salt forms (HC...  
WO/2015/178507A1
A composition for enhancement of ability to concentrate and method of improving ability to concentrate using alanylglutamine or a salt of alanylglutamine as an active ingredient.  
WO/2015/179492A1
Methods for preparing nucleic acid nanoparticles having a controllable shape and their use for delivering nucleic acids to a subject in need of treatment of a neurological disease are disclosed.  
WO/2015/178414A1
 Provided is a method for monomerizing an MMP-7 aggregate. An MMP-7 monomerization method comprising treating an MMP-7 aggregate with a buffer solution including a low concentration of a monovalent cation chloride (such as sodium chlor...  
WO/2015/179867A1
The present invention provides a dendritic cell-based vaccine against a-synuclein, antibodies against a-synuclein, and methods of treating, preventing, and/or vaccinating against Parkinson's Disease (PD). In one aspect, the present inven...  
WO/2015/179559A2
Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of MAGL, ABHD6, and FAAH. Furthermore, the subject compounds...  
WO/2015/176167A1
A method of using Argon gas for treating a condition associated with mu opioid receptors and/or the vesicular monoamine transporter activity in a mammal, condition selected from: anxiety, nervousness, tension, jumpiness, excitability, re...  
WO/2015/177435A1
The invention relates to a drug combination including xenon gas and at least one antioxidant, in liquid or solid form, for use in treating, slowing, or preventing neurological damage following a neurodegenerative disease in a human being...  
WO/2015/177688A1
Compounds of the general formula (I), wherein one of X1 and X2 represents N, and the other one of X1 and X2 represents -C(CH3), A represents unsubstituted or substituted 5-, 6-or 10-membered aryl or heteroaryl, n is 0 or 1 and B is a bic...  
WO/2015/178404A1
The present invention addresses the problem of discovering a carotenoid compound exhibiting excellent water solubility. Provided is a carotenoid derivative represented by general formula (I) [in general formula (I): X represents a carbon...  
WO/2015/179258A2
The present invention provides a method of administering a therapeutic agent directly to the brain parenchym through a compromised region of the blood-brain barrier in a subject having a brain disorder, that involves first disrupting the...  
WO/2015/179258A3
The present invention provides a method of administering a therapeutic agent directly to the brain parenchym through a compromised region of the blood-brain barrier in a subject having a brain disorder, that involves first disrupting the...  
WO/2015/176801A1
The invention relates to transdermal therapeutic systems (TTS) containing lavender oil as active substance and to their use in the prevention and/or treatment of excitation, sleep disturbances, anxiety and nervousness, in particular of e...  
WO/2015/177110A1
The present invention is concerned with indolin-2-one and l,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general formula (I) wherein Ar1 is phenyl, pyridinyl or pyrimidinyl; Ar2 is a 5 or 6 membered heteroaryl group, containing 2...  
WO/2015/179125A1
Methods are disclosed for treating multiple sclerosis comprising administering an agent that reduces expression and/or activity of Allograft inflammatory factor- 1 (Aif-1) in a subject and for screening for such agents.  
WO/2015/176800A1
The invention relates to a transdermal therapeutic system in the form of a plaster, for administering the active agent amitriptyline. Said system has a back layer which is impermeable to the active agent, an active agent reservoir which ...  
WO/2015/175974A1
Provided herein are methods and composition for the treatment for macrophage-related disorders, for example through the use of biomarkers for selection of responders and treatment monitoring.  
WO/2015/176069A3
Analogs of (4aS,6R,8aS)- 5,6,9,10,11,12- hexahydro- 3-methoxy- 11-methyl- 4aH- [1]benzofuro[3a,3,2-ef] [2] benzazepin- 6-ol of the formula: wherein R1 is carbamate, carbonate or carboxylate group; R2 is alkoxy group of from one to six ca...  
WO/2015/173225A1
The present invention relates to deuterated and optionally detectably labeled compounds of formula (I): R1-A-R2 and formula (V) and salts thereof, wherein Rl, R2, A, and X10-X19 have any of the values defined in the specification. Also i...  

Matches 401 - 450 out of 110,331